TriSalus Life Sciences Reports Q2 2026 Results

What Happened
On August 6, 2026, TriSalus Life Sciences, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release. That press release is attached to the Form 8-K as Exhibit 99.1. The Form 8-K was signed by Chief Financial Officer David Patience on August 6, 2026. The company notes the press release and Exhibit 99.1 are furnished (not “filed”) and therefore are not subject to Section 18 liability or automatically incorporated by reference into other filings.

Key Details

• Press release announcing Q2 results issued on August 6, 2026.
• Quarter covered: three months ended June 30, 2026.
• Press release attached as Exhibit 99.1 to the Form 8-K.
• Form 8-K signed by CFO David Patience; Inline XBRL cover page (Exhibit 104) included.

Why It Matters
This filing notifies investors that TriSalus has released its quarterly earnings and operational results — key information for evaluating near-term performance, revenue trends, cash position and guidance. Investors should read the attached press release (Exhibit 99.1) for the company’s reported earnings, revenue, expenses, and management commentary. Note the disclosure is furnished rather than filed, which affects Section 18 liability and incorporation into other SEC filings.